| 4.62 0.17 (3.82%) | 07-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.12 | 1-year : | 20.97 |
| Resists | First : | 12.09 | Second : | 17.95 |
| Pivot price | 5.31  |
|||
| Supports | First : | 2.59 | Second : | 2.16 |
| MAs | MA(5) : | 5.09  |
MA(20) : | 4.72 |
| MA(100) : | 3.27 |
MA(250) : | 3.78 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 14.1 |
D(3) : | 16.2 |
| RSI | RSI(14): 49.9 |
|||
| 52-week | High : | 17.95 | Low : | 2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ UPC ] has closed above bottom band by 42.2%. Bollinger Bands are 366.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.71 - 4.74 | 4.74 - 4.77 |
| Low: | 4.22 - 4.25 | 4.25 - 4.29 |
| Close: | 4.56 - 4.62 | 4.62 - 4.68 |
Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These remedies are designed to address common chronic health issues prevalent among the elderly, promoting physical well-being and longevity, in addition to offering medications for cold and flu symptoms. Beyond its own manufactured goods, UPC also functions as a distributor and vendor for a diverse range of third-party products. This extensive portfolio includes biomedical drugs, medical instruments, traditional Chinese medicine 'pieces' (raw ingredients), and various dietary supplements. Its clientele spans across the healthcare sector, encompassing other pharmaceutical companies, hospitals, clinics, and major drugstore chains. Established in 2019, the company's operations are headquartered in Ji'An, China, and it functions as a subsidiary of Sununion Holding Group Limited.
Sat, 11 Jul 2026
Universe Pharmaceuticals Inc Stock Short Interest Rises to 38.12% - Quiver Quantitative
Fri, 10 Jul 2026
Price to book forward of Universe Pharmaceuticals Inc – NASDAQ:UPC - TradingView
Mon, 29 Jun 2026
China's Universe Pharmaceuticals (NASDAQ: UPC) Makes Nasdaq Top Gainer List on Acquisition News - Investorideas.com
Mon, 29 Jun 2026
Nasdaq Jumps More Than 1%; Comcast Shares Spike Higher - Benzinga
Mon, 29 Jun 2026
UPC Stock Jumps As Universe Pharmaceuticals Announces Patent-Focused Deal - timothysykes.com
Fri, 26 Jun 2026
Universe Pharmaceuticals bets $10.8M on five China patents - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 1 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 11.3 (%) |
| Held by Institutions | 4.4 (%) |
| Shares Short | 239 (K) |
| Shares Short P.Month | 9 (K) |
| EPS | -7.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 99.63 |
| Profit Margin | -20.6 % |
| Operating Margin | -6.8 % |
| Return on Assets (ttm) | -2.7 % |
| Return on Equity (ttm) | -7.3 % |
| Qtrly Rev. Growth | -14.2 % |
| Gross Profit (p.s.) | 9.97 |
| Sales Per Share | 28.27 |
| EBITDA (p.s.) | -3.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.6 |
| PEG Ratio | 0 |
| Price to Book value | 0.04 |
| Price to Sales | 0.16 |
| Price to Cash Flow | -0.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|